NTI Rundown + Clinical trial update, page-423

With the Italy deal they have inculded the following statement

At least ~20,000 units would need to be purchased over this period (2017 – 2019) if distributor wishes to retain exclusivity post initial term

Obviously there is no guarantee the sales will hit this level but I believe the company sees this as a reasonable target. Now add in the other countries targeted and the number very quickly balloons. Entering Germany, the UK, France and Australia next year. So we would hopefully be up to 100,000 in next three years.
The uptake in Italy will show how successful this will be and I am sure if they sell well we will have feedback quickly.